Feminine hygiene market expected to grow to $35.2 billion by 2024

As the usage of feminine hygiene products continues to increase worldwide, researchers are making predictions on how much money the increase could spawn.

According to a new report from Persistence Market Research, a third-platform research firm in New York, the global feminine hygiene market is expected to grow 7.2 percent over the next eight years and be worth $35.2 billion by 2024.

Sanitary napkins and pad products are expected to grow the most and be valued at $16.8 billion.

Experts are attributing much of the growth to the adoption of feminine hygiene products in developing countries as they continue to gain popularity. Countries in South Asia are expected to post a high increase over the next eight years since they dominated the market in 2015. Additionally, feminine hygiene products are becoming more available and affordable, which the study predicts will also contribute to the industry’s growth.

To view the whole report, click here.

Katherine Davis,

Senior Writer

As a Senior Writer for TriMed Media Group, Katherine primarily focuses on producing news stories, Q&As and features for Cardiovascular Business. She reports on several facets of the cardiology industry, including emerging technology, new clinical trials and findings, and quality initiatives among providers. She is based out of TriMed's Chicago office and holds a bachelor's degree in journalism from Columbia College Chicago. Her work has appeared in Modern Healthcare, Crain's Chicago Business and The Detroit News. She joined TriMed in 2016.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.